Facebook Linkedin Twitter
Inside Precision Medicine Bayer and NextRNA Sign $500M+ IncRNA Oncology Deal 

Bayer AG

ribonicleic acid chain from which can be used to make RNA silencing treatments for conditions such as congenital melanocytic nevus syndrome
News & Features

Bayer and NextRNA Sign $500M+ IncRNA Oncology Deal 

0
Multicultural society and international tolerance, african, asian, american and caucasian culture integration and pride
News & Features

Why Equity Needs to Become Obligatory

Anita Chakraverty
0
Side view of emotionally stressed mid adult woman standing in the kitchen next to a blister of pills
News & Features

Bayer’s Elinzanetant Shines in Phase III, Heating up Menopause Drug Market

0
Close up of a cancer cell - oncology target 3d illustration
Informatics

Recursion Pharma Sharpens Oncology Focus with Potential $1.5B Bayer Collaboration

0
Two medical doctors shaking hands
News & Features

Twist Bioscience, Bayer Enter Antibody Discovery Deal Valued at up to $188 Million

0
Scientist holding a DNA sample with the results on a computer screen in a laboratory
Molecular Dx

Boundless Raises $100M in Series C to Fuel Extrachromosomal DNA Drug

0
Coronavirus RNA strand
Molecular Dx

ReCode Therapeutics Raises $200M in Series B

0
Cancer cells, illustration
News & Features

Illumina’s TruSight Test in EU Gets Companion Dx Indication  

0
Two medical doctors shaking hands
Molecular Dx

Bayer, Life Raft Group Collaborate to Improve Access to CGP for GIST Patients

0
Gloved hand holding COVID-19 vaccine such as the mRNA vaccine developed by Arcturus Therapeutics in syringe on a background of SARS-CoV-2 particles
Coronavirus

What Can We Expect From The Second Wave of Coronavirus Vaccines?

Helen Albert
0
12Page 1 of 2

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine